Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 73
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 37
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Satyam Singh, Sushabhan Sadhukhan, Avinash Sonawane
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188967-188967
Closed Access | Times Cited: 33
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Darin Poei, Sana Ali, Shirley Ye, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 8
Loss of DDX24 inhibits lung cancer progression by stimulating IKBKG splicing-mediated autophagy
Siwen Sun, Xiaomeng Jing, Guangquan Tong, et al.
Theranostics (2025) Vol. 15, Iss. 5, pp. 1879-1895
Open Access | Times Cited: 1
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 21
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer
Shirui Wang, Dan Luo, Chunlan Pu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 248, pp. 115082-115082
Open Access | Times Cited: 13
Drp1: Focus on Diseases Triggered by the Mitochondrial Pathway
Fulin Sun, Min Fang, Huhu Zhang, et al.
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 2, pp. 435-455
Closed Access | Times Cited: 5
SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma
Zhenyao Huang, Xia Chen, Yun Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
WDR62 mediates MAPK/ERK pathway to stimulate DNA damage repair and attenuate cisplatin sensitivity in lung adenocarcinoma
Li Xu, Yingwei Guo, Zecheng Qi, et al.
Anti-Cancer Drugs (2025)
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Computational strategies for PROTAC drug discovery
Jia Wu, Wanhe Wang, Chung‐Hang Leung
Acta Materia Medica (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 11
Advances in metal-based nano drugs and diagnostic probes for tumor
J. Ding, Zhijing He, Yujia Zhai, et al.
Coordination Chemistry Reviews (2023) Vol. 501, pp. 215594-215594
Closed Access | Times Cited: 11
The role of E2F2 in cancer progression and its value as a therapeutic target
Yang Gao, Xinjie Qiao, Zhenhui Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Advances of E3 ligases in lung cancer
Jingwen Yu, Yiqi Zhao, Yue Xie
Biochemistry and Biophysics Reports (2024) Vol. 38, pp. 101740-101740
Open Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
M. Malarvannan, S. Unnikrishnan, S. Monohar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107984-107984
Closed Access | Times Cited: 3
Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer
Yang Xie, Jiao Ma, Wenxin Tang, et al.
Clinical Nuclear Medicine (2024) Vol. 49, Iss. 9, pp. 830-837
Closed Access | Times Cited: 2
Development of PROTACS degrading KRAS and SOS1
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
Jennifer X. Qiao, D. Keith Williams, Patrice Gill, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review
Bahareh Farasati Far, Maryam Safaei, Fatemeh Mokhtari, et al.
Medical Oncology (2023) Vol. 40, Iss. 6
Closed Access | Times Cited: 6
Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras
Gerhard Hamilton, Sandra Stickler, Barbara H. Rath
Current Pharmaceutical Design (2023) Vol. 29, Iss. 22, pp. 1741-1746
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top